Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
about
Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccineBinary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsAnthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinHuman anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbedIdentification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression systemSpecific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigenContribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccineRabbit and nonhuman primate models of toxin-targeting human anthrax vaccinesSerology and anthrax in humans, livestock and Etosha National Park wildlifeAnthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccinesMucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.Evaluation of combinatorial vaccines against anthrax and plague in a murine modelAnthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigenSearch for correlates of protective immunity conferred by anthrax vaccine.Anthrax spores make an essential contribution to vaccine efficacyA recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.Development of an improved vaccine for anthraxBacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonalitySerological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis.Quantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats.Protective immunity induced by Bacillus anthracis toxin-deficient strains.Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.Death at Sverdlovsk: what have we learned?Global metabolomic analysis of a mammalian host infected with Bacillus anthracis.A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaquesInformation on which to base assessments of risk from environments contaminated with anthrax sporesQuantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.Pathology and pathophysiology of inhalational anthrax in a guinea pig model.Domain specificity of the human antibody response to Bacillus anthracis protective antigen.Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.Protection against anthrax with recombinant virus-expressed protective antigen in experimental animalsImmunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen.Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.Bacillus anthracis lethal toxin represses MMTV promoter activity through transcription factorsProgress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.Anthrax lethal toxin and the induction of CD4 T cell immunity.
P2860
Q23912118-3A7E5A6B-1AE7-4CA8-B793-D9ED869BBDE9Q24562788-6C1E3087-A595-4AB0-9EAC-B4B4AA16AD58Q24796044-5BF531E6-F031-46C5-8F32-5E5AC128E371Q24806902-23907E57-824F-41F7-A86B-FB6CCABF1A4CQ28388913-56EA3022-0B8C-4D36-A064-1B6A54B42F67Q28390541-E47EE743-48AB-46F2-B114-7ED240E57612Q28393904-A079E4AC-A299-44AE-B3C2-CC9FE46B8B8BQ28398013-D2C7A78B-CACF-422B-A074-4255880101ACQ28767304-1003E21C-5FFD-4702-9CF4-545A6E563BDBQ30407662-D0424022-ED23-4F64-ADFD-EF0CD35AD77FQ30651835-1B93CCA1-34D8-45E8-BA5E-A2CAEC5F8499Q31126626-DD217AA6-9D72-4D19-BA9A-451FE3F2BA28Q32066443-A9505D36-417C-4E04-9216-2925C142F000Q33283821-8F061341-1B47-4306-92D3-C224D53D17BDQ33783323-C8E0D11B-2AA2-4902-95FD-33B9FF498168Q34000174-7690CA25-9F84-448C-A295-9850334C54FCQ34007168-6AC3F7AF-B937-418D-A222-0AC3191C97EAQ34117857-74340B56-2D18-4DC3-943F-228B92A1DAC8Q34119476-8240BC6C-F74F-4FDE-9559-7CD9D03FF3DBQ34289924-0AE39989-E077-44EB-9B93-E9919ECFFB27Q34744925-75D26B99-D8B5-4D49-84AD-F4FA92BD6ACDQ34774876-57AF9144-58DE-4F7C-82FA-132BF6DA5EBDQ35026166-5B74B497-DF5D-4C9C-9C51-855222C72F28Q35077052-A84946E2-7D2A-4E56-AABD-BF73B4A962F7Q35400677-F22E2146-A4C8-4603-89B7-5566A04E47B2Q35652068-029F4190-902C-4937-8D90-1332F59534A6Q35834195-2E6DE902-84FA-43CE-840C-D25F5D9CADC0Q36281318-3C17AD0B-E86C-4080-8ABD-1D3970A9AACFQ36378590-EE0E8CFD-98A9-4109-8E0B-54C202CBCC61Q36503667-42E8929F-677F-4064-A24D-9D1F31178CC0Q36735532-43FC036C-3059-4C6D-8E17-79C9A0EAFDB3Q36804713-8DFB921F-1F94-434C-BC43-8AC1B18B507BQ36876723-F0A8FCD3-CE10-4E44-B5B7-D0DB32A6DA8DQ36958363-721A8390-A8D9-4E71-A364-87CA54F55909Q36964618-7037F268-FE8C-4763-89A5-C063EDFC0BCCQ36976315-14975C7C-B14B-460C-81B6-84C6C8D5591BQ36980383-1F1CD31F-6188-46FF-BDA3-B659B60B8A8AQ37368280-1094332E-FFA0-4F20-B255-4AA04ACE11C6Q37424982-61704F40-C940-4D87-96D3-1E683AFB3215Q38060730-50267CD0-3B22-47C7-8439-1382B72D89D5
P2860
Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Development of antibodies to p ...... evance to protective immunity.
@en
type
label
Development of antibodies to p ...... evance to protective immunity.
@en
prefLabel
Development of antibodies to p ...... evance to protective immunity.
@en
P2093
P2860
P1476
Development of antibodies to p ...... evance to protective immunity.
@en
P2093
Broster MG
Manchee RJ
Turnbull PC
P2860
P304
P407
P577
1986-05-01T00:00:00Z